Effect of Lactocare® Synbiotic on Disease Severity in Ulcerative Colitis: A Randomized Placebo-Controlled Double-Blind Clinical Trial

Content Provider	Semantic Scholar
Author	Amiriani, Taghi Rajabli, Niloofar Faghani, Maryam Besharat, Sima Roshandel, Gholamreza Tabib, Atefeh Akhavan Joshaghani, Hamidreza
Copyright Year	2020
Abstract	BACKGROUND Inflammatory bowel diseases are managed by different methods, which may not be well tolerated because of their side effects. Recently, pro-prebiotics are considered as a supplementary treatment in gastrointestinal diseases. In this study, the effect of Lactocare® (ZistTakhmir Company) was investigated on the disease severity in mild to moderate ulcerative colitis. METHODS In this randomized, double-blind clinical trial (Iranian Registry of Clinical Trials number: IRCT201407271264N5), 60 patients with mild to moderate ulcerative colitis were included. An 8-week trial was carried out comparing Lactocare® as a supplement with standard therapy against placebo. Simple Clinical Colitis Activity Index (SCCAI) was measured at baseline and after 8 weeks. Statistical analysis was performed using paired ttest to assess the temporal changes (before and after the treatment) in the mean of SCCAI in each group. Chi-square test was used to compare the response rates. Odds ratios (OR) and the 95% confidence intervals (95%CI) were also calculated. p values of less than 0.05 were considered significant. RESULTS A significant decreased mean SCCAI was seen in the intervention group (4.56 ± 2.56) vs. placebo group (6.54 ± 2.47) (p < 0.05). Response to treatment was seen in 64.3% of the treatment group vs. 47% in the placebo group (p = 0.18). Response to treatment was observed in 90.9% of patients with ulcerative colitis for more than 5 years compared with 44.4% of the control group (p = 0.01). CONCLUSION Regarding the effectiveness of pre-probiotics in mitigating symptoms in patients with ulcerative colitis, it could be suggested to try pre-probiotics in the standard treatment particularly in those with more than five years ofthe disease.
Starting Page	27
Ending Page	33
Page Count	7
File Format	PDF HTM / HTML
DOI	10.15171/mejdd.2020.160
PubMed reference number	32082518
Journal	Medline
Volume Number	12
Alternate Webpage(s)	https://www.mejdd.org/index.php/mejdd/article/download/2127/2131
Alternate Webpage(s)	http://mejdd.org/lib/index.php/mejdd/article/download/2127/2131
Alternate Webpage(s)	https://doi.org/10.15171/mejdd.2020.160
Journal	Middle East journal of digestive diseases
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article